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The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a
new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by
the involved pharma company with the cost of treatment for patients not responding after a
4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost
of 6 weeks (42 days) treatment for other patients discontinuing (Cost Sharing, CS). The aim
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of our study was to describe the Sativex discontinuation profile from a large population of
spasticity treated Italian MS patients.
Methods
We collected data of patients from 30 MS centres across the country starting Sativex
between January 2014 and February 2015. Data were collected from the mandatory Italian
Medicines Agency (AIFA) web-registry. Predictors of treatment discontinuation were
assessed using a multivariate Cox proportional regression analysis.
Results
During the observation period 631 out of 1597 (39.5%) patients discontinued Sativex. The
Kaplan-Meier estimates curve showed that 333 patients (20.8%) discontinued treatment at
4 weeks while 422 patients (26.4%) discontinued at 6 weeks. We found after adjusted
modeling that a higher NRS score at T1 (adjHR 2.23, 95% 2.07–2.41, p<0.001) and a lower
baseline NRS score (adjHR 0.51 95% CI 0.46–0.56, p<0.001) were predictive of treatment
discontinuation.
Conclusion
These data show that the first 6 weeks are useful in identifying those patients in which Sati-
vex could be effective, thus avoiding the cost of longer term evaluation.
Introduction
Spasticity is a common symptom in multiple sclerosis(MS) patients [1,2]. Spasms, pain, poor
sleep quality, and urinary dysfunction are symptoms frequently associated with spasticity in
MS [3]. The medications for generalized spasticity such as baclofen, tizanidine, dantrolene,
and benzodiazepines, are not considered fully effective in reducing spasticity associated symp-
toms [4–6]. The approval of 9-delta-tetrahydocannabinol and cannabidiol (THC:CBD) oro-
mucosal spray (Sativex),changed the management of spasticity and related symptoms in MS
patients [7,8]. The efficacy of Sativex oromucosal spray as add-on therapy for symptoms
improvement in MS patients with moderate to severe spasticity has been demonstrated in sev-
eral clinical trials [9–11,7,12]. The largest pivotal phase III, enriched-design clinical trial
included MS patients with moderate-severe spasticity, corresponding to a patient-reported
0–10 numerical rating scale (NRS) score4, resistant to first line medications. After a first 4
weeks single-blind THC:CBD trial period, about 47% of the patients showed an initial
response, and 2/3 of them kept on improving later on. In particular the patients after the first
phase of the study showed a decreased of 3.01 points in the NRS score (from a baseline score
of 6.91 to a score of 3.9). In the second phase of the study the patients in the active treatment
group showed a further improvement of the NRS spasticity score (by 0.04 units from a baseline
score of 3.87). The difference in mean NRS score between the placebo group and the active
treatment group was statistically significant (0.84 points, p = 0.0002). About 50% of patients
reported adverse events, being mild to moderate dizziness and fatigue the most common treat-
ment-related adverse event [12]. In post-approval published observational studies patients
tend to use lower doses compared with clinical trials (6–7 sprays/d vs.>8) and the incidence
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of adverse events was lower, with no evidence of addiction, abuse, misuse or memory
impairment [13].
In Italy, the Italian Medicines Agency is adopting a reimbursement approach for new medi-
cations named Managed Entry Agreement (MEA). The Italian Medicines Agency agreement
for Sativex considers both a payment by result (PbR) method and a cost sharing method (CS).
The PbR consists of a complete reimbursement of all non-initial responder patients by the
company (a 100% payback), whereas the CS consists of a 50% of reimbursement for patients
on treatment for 6 weeks (GU Serie Generale n.100 del 30-4-2013—Suppl. Ordinario n. 33).
According to the Italian Medicines Agency, the 4 weeks trial period “non-responders” have to
discontinue treatment. For tracking these conditions, an e-Registry for all the patients starting
Sativex was established in the Italian Medicines Agency website. Given the growing impor-
tance of data derived from real world observational studies, we decided to collect information
about Sativex use in Italy, using the Italian medicine agency prospective e-registry designed to
collect efficacy, tolerability and safety data. The Italian Medicines Agency e-registry, manda-
tory for all patients receiving Sativex in Italy, was used as a main prospective source database.
It would bring a comprehensive picture of Sativex effect, minimizing biases. For further infor-
mation, we also used complementarily the involved patients’ medical charts retrospective
review. In a recent first publication derived from this database analysis, we found that Sativex
was effective with no unexpected AEs, abuse and misuse. We found 70.5% of patients reached
a20% improvement (initial response, IR) and 28.2% reached a30% improvement (clini-
cally relevant response, CRR). The mean number of spray was 6.8 per day at T1. During the
observation period a total of 631 patients (39.5%) discontinued treatment [14]. The main aim
of this study was to further describe Sativex discontinuation and adverse events profile in this
large population of Italian MS patients. In addition, we analyzed discontinuation time for lack
of efficacy and adverse event reasons, considering the outcome-based risk and cost sharing
Italian agreement time frames (4 weeks and 6 weeks).
Material and methods
Design and setting
All patients included in the study database were treated in accordance with the approved label
and expected standards of good clinical practice. Complementary clinical and demographic
parameters were acquired retrospectively from the patients’ medical records.
The study was approved by the Policlinico-Vittorio Emanuele (Catania, Italy) Ethics Com-
mittee (n˚ 37/2015/PO) and as required, by the Ethics Committee of the other participating
centres. Given the observational design of the study, consent form was not required (according
to the Italian law).
Patients were consecutively included in the e-registry at the start of Sativex treatment (base-
line) and followed prospectively up to 6 months each, with data collection at baseline(T0),
after 4 weeks (T1), after 12 weeks (3 months, T2) and after 24 weeks (6 months, T3) from base-
line. We continued the observation up to 730 days (2 years since baseline) to register time to
discontinuation according to our clinical practice. We considered the 4 weeks and 6 weeks to
determine Sativex discontinuation time.
Patient population
The AIFA registry establishes that patients are eligible for starting Sativex add-on treatment
when fulfilling the following approved label related inclusion criteria: MS patients older than
18 years, with moderate to severe spasticity (0–10 Numerical Rating Scale (NRS) score4)
and not responding to common and ongoing antispastic drugs (used under their approved
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label). Other exclusion criteria were: severe cardiovascular diseases, past history of psychiatric
diseases, use of street cannabis and/or other psychoactive drugs, pregnancy and MS spasticity
NRS score <4.
The 30 MS participating centres collected all patients’data from the AIFA Sativex e-registry
website. MS spasticity evolution was evaluated by the 0–10 NRS patient rated scale(0 = no,
10 = maximal spasticity)[15]. MS physical disability was evaluated using the expanding disabil-
ity status scale(EDSS). Other parameters such as use of other antispastic drug, previous anti-
spastic drugs and treatment discontinuation were collected. Furthermore, complementary
demographical and clinical history data, tolerability, daily dose (n˚ of spray per day), overall
clinical response to Sativex, discontinuation reason(s) and time to discontinuation were col-
lected from patients’ medical charts. Data were manually entered in an ad hoc created database
and were double entered into the database. Data cleaning was also performed before the data
analysis. Tolerability was assessed collecting data, after prompted question to the patient dur-
ing web registry data entry, about each adverse event (AE) and serious adverse event (SAE)
occurring during the whole study period, in accordance with the pharmacovigilance regula-
tions. Dataset of all patients ‘records are available as supporting information (S1 File).
Statistical analysis
Data were analyzed using the STATA 11.0 software packages [16]. Data cleaning was per-
formed before the data analysis considering both range and consistency checks.
Quantitative variables were described using means and standard deviations (SD). The dif-
ference between means and the difference between proportions were evaluated by the t-test
and the Chi-square test respectively. A Shapiro-Wilk test was performed to assess the normal
distribution of data. In case of not normal distribution appropriate non-parametric tests were
performed. A Kaplan–Meier survival curve was plotted to provide estimates of treatment fail-
ure by time. The Log-rank test was used for the univariate analysis of categorical analysis
whereas the Cox proportional hazard ratio was used for the univariate analysis of continuous
variables. Predictors of treatment discontinuation were assessed using a multivariate Cox pro-
portional regression analysis. We considered “treatment failure, yes/no” as the dependent vari-
able and age, sex, disease duration, MS type, baseline EDSS, baseline NRS and NRS at T1 as
independent variables. In the absence of discontinuation event, data were censored at the last
observation day. Multivariate analysis was performed to investigate the independent effect of a
risk or protective factor after adjustment for one or several other factors or to adjust for inter-
actions between covariates, when significant. Parameters associated with the outcome at the
univariate analysis with a threshold of p = 0.20–0.25 were included in the multivariate model.
The multivariate modeling analysis was adjusted for age and sex. Interactions between covari-
ates were examined in the multivariate models. The likelihood-ratio test was performed to
compare the model with interactions and the model without interactions.
Results
A total of 1615 patients with MS spasticity starting treatment with Sativex were recruited from
30 Italian MS large centers distributed geographically across the nation. Recruited patients
started treatment between January 1st 2014 and end of February 2015 (see Table 1 for demo-
graphics and clinical details). Out of the 1615 patients, 18 patients were excluded from the
analyses because their baseline NRS score was not available, leading to a 1597 analyzable
patients’ sample. A total of 704,009 exposed patients/days were analyzed, with a median fol-
low-up time of 730 days (2 years) (range 2–730).
Sativex in resistant MS spasticity
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Out of the study population of 1597 patients, 631 (39.5%) discontinued therapy during the
observation period. Out of them,396 patients (24.8% from the overall sample) did not reach
the 20% NRS score improvement vs. baseline initial response (IR) threshold at T1. Out of the
631, a total of 374 patients do not reach T2 visit (discontinued after T1).
Reasons for discontinuation during the whole observation period were (multiple answer
possible) lack of effectiveness (n = 371, 23.2%), adverse events (n = 260, 16.3%), non-adher-
ence (n = 12, 0.8%), lost at follow-up (n = 7, 0.4%) patient’s choice (n = 5, 0.3%) or reasons not
available (n = 32, 2%). For AE and SAE details see our previous paper [14].
The Kaplan-Meier survival curve showed that 333 patients (20.8%) discontinued treatment
within 4 weeks while 422 (26.4%) discontinued within 6 weeks. Time to discontinuation was
analyzed as hazard ratio (HR) to identify clinical and demographic characteristics predictive of
a higher risk of treatment failure.
We found after adjusted modeling that the NRS score at T1 visit was predictive of treatment
discontinuation (adjHR 2.23, 95% 2.07–2.41, p = 0.000). In other words, if the NRS score at T1
increases by one point, while the others variables are held constant, the hazard of Sativex dis-
continuation increases by two-fold. Additionally baseline NRS score was also associated to the
outcome (adjHR 0.51 95% CI 0.46–0.56, p<0.001). In particular, as the baseline NRS score
increases by one point, while the others variables are held constant, the hazard of Sativex dis-
continuation decreases by 49% (See Table 2).
Table 2. Multivariate analysis of predictors of discontinuation.
Discontinuation adjOR p 95% CI
NRS T0 0.51 <0.001 0.46–0.56
NRS T1 2.23 <0.001 2.07–2.41
Legend: NRS = Numerical Rating scale; T0 = baseline; T1 = after 1 month; adjOR = adjusted odds ratio.
https://doi.org/10.1371/journal.pone.0180651.t002




Relapsing Remitting MS (%) 311 (19.5)
Secondary Progressive MS (%) 1029 (64.4)
Primary Progressive MS (%) 255 (16)
Age (years, mean, range) 51 (21–84)
Disease duration (years, mean±SD) 17.5 ± 8.6
Baseline EDSS (median, range) 6.5(1.5–9.5)
NRS score T0, Baseline(n = 1597 pts,mean±SD) 7.5 ± 1.4
NRS score T1, Month 1(n = 1432 pts,mean±SD) 5.9 ± 1.6
NRS T2, Month 3 (n = 889 pts,mean±SD) 5.1 ± 1.6
NRS T3 Month 6 (n = 593 pts,mean±SD) 4.8 ± 1.7
Dose, puffs number T1(mean±SD) 6.8 ± 2.6
Dose, puffs number T2 (mean±SD) 6.5 ± 2.6
Dose, puffs number T3 (mean±SD) 6.3 ± 2.8
Legend: MS = Multiple Sclerosis, EDSS = Expanded Disability Status Scale, NRS = Numerical rating scale,
T0 = baseline, T1 = after 1 month, T2 = after 3 months, T3 = after 6 months.
For 2 patients disease course was not available.
https://doi.org/10.1371/journal.pone.0180651.t001
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According to non-response or AE as reason for discontinuation we divided our cohort in
two groups. When the patients discontinued for multiple reasons we considered “non-
response” as the main reason of discontinuation. We found a total of 376 patients considered
as non-responders and 209 patients who discontinued just for AE. A Kaplan-Meier survival
analysis showed that 203 of the non-responder patients (53.9%) discontinued treatment after
exactly 4 weeks (28 days) while 257 (68.3%) discontinued after 6 weeks (42 days). In the group
of patients discontinuing just for AE, we found 80 patients (38.3%) discontinued after 4 weeks
(28 days) while 97 (46.4%) within 6 weeks (42 days). A log-rank test showed a significant dif-
ference in survival function between these groups (p = 0.0016) (see Fig 1).
Discussion
This study showed that 39.5% of patients discontinued Sativex during the whole observation
period. In particular, almost 25% of those patients did not reach the 20% initial response
reduction in their NRS score, considered the threshold for treatment effectiveness. Reasons for
discontinuation during the whole observation period were lack of effectiveness for 23.2% of
patients and adverse events for 16.3% of patients (see Fig 1). In the overall group of discontinu-
ing patients the Kaplan-Meier survival curve showed that 20.8% (333) patients discontinued
treatment after 4 weeks while 422 (26.4%) discontinued after 6 weeks (see Fig 2). These data
suggest that the initial response (IR) threshold is appropriate for identifying those patients
more prone to respond to Sativex effects, although survival estimates apparently may seem in
contrast with discontinuation percentage (almost 25% did not reach IR). The Italian Medicines
Agency web registry, always requiring the IR threshold before Sativex dispensation, could in
part explain this assumption. It could be postulated that in the real life setting the NRS score
evaluation was delayed beyond four weeks to better define the response to treatment. This
could be in part demonstrated by the survival curve, showing 26.4% of patients discontinued
after 6 weeks and by our previous study, showing a percentage of 9.3% of patients considered
clinically partial responder by physicians at T1 [14].
Fig 1. Kaplan-Meier survival estimates. Kaplan-Meier survival estimates showing the time to treatment
failure for lack of efficacy and adverse events.
https://doi.org/10.1371/journal.pone.0180651.g001
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These data showed that the 4 weeks trial is effective in identifying those patients where Sativex
could be effective, thus limiting the economic burden of Sativex on the health system. To reduce
costs and improve savings for the Italian health system, a response-based risk-sharing agreement
between the Italian Medicines Agency and the company distributing Sativex, was implemented
[17]. According to the agreement, the health system avoids the cost of early non-responders,
being reimbursed if the outcome is not reached, saving resources. After the 4 weeks period it is
seen a discontinuation rate of 20.4% of exposed patients, while after the 6 weeks period we see a
26.4% discontinuation rate. The pharmaceutical company will have to reimburse 100% of the
patients failing at 4 weeks and 50% of all patients reaching 6 weeks (for both reasons). This
means that the Italian Medicines Agency, related to our sample, will get fully reimbursed for the
20.4% patients not responding after 4 weeks and for 50% of those reaching 6 weeks, fulfilling the
payment by results and cost sharing concepts [18]. The Italian Medicines Agency got reimbursed
for about 66% of non-responder Sativex population within the first 6 weeks, suggesting the MEA
represent a good tool for payers, avoiding the wasting of resources for patients not adequately
responding. In particular considering the PbR reimbursement was 436.81 euros for 333 patients
whereas the CS reimbursement was 218.40 euros for 89 patients, AIFA got a total reimbursement
of 164,895.775 euros (145,457.73 + 19,438.045).
The multivariate analysis showed that the NRS score at T1 was predictive of treatment dis-
continuation (adjHR 2.23).
In other words, if the NRS at T1 increases by one point, the probability of Sativex discontin-
uation increases by two fold. This is in line with the initial responder definition, requiring a
20% improvement of NRS score at T1 compared to T0. Additionally, the baseline NRS score
was also associated to the outcomes (adjHR 0.51). In particular, if the baseline NRS score
increases by one point, the hazard of Sativex discontinuation decreases by 49%. Overall, higher
NRS scores are related to a higher probability to be a responder and a lower probability to stop
treatment. An increase of NRS score at T1 reflects the worsening of spasticity despite Sativex
treatment, suggesting a higher probability of treatment discontinuation. This is in line with the
results of our previous study showing higher NRS score is associated to a higher probability to
Fig 2. Kaplan-Meier survival estimates. Kaplan-Meier survival estimates showing the time to treatment
failure for patients.
https://doi.org/10.1371/journal.pone.0180651.g002
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be a responder [14]. However, as mentioned in our previous study, the observational design
and the use of patient reported spasticity score, can in part affect our findings [19].
In conclusion, we observed that Sativex is a good option for a large number of MS patients
complaining of moderate to severe resistant spasticity. The 4–6 weeks trial period is a reliable
tool to identify those patients responding to treatment, limiting the economic burden of Sati-
vex on the national health system, charging most of the effectiveness failure risks to the phar-
maceutical company while adding a cost sharing side. Considering the increasing cost for the
society of standard of care treatment of MS patients spasticity related disability and the nega-
tive impact on their quality of life, we may suggest Sativex should be considered as the add-on
treatment of choice for MS patients failing to achieve enough relief with first-line classic anti-
spastic oral options [20]. Further research is needed to verify if Sativex could be used as a treat-
ment option in different spasticity conditions other than MS and for MS symptoms other than
spasticity, as a first line option or as add-on.
Supporting information
S1 File. Dataset of all patients’ records used for the data analysis.
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